Status:
COMPLETED
A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned
Lead Sponsor:
Eli Lilly and Company
Conditions:
Carcinoma, Small Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purposes of this study are to determine 1) the safety of pemetrexed and any side effects that might be associated with it 2) whether pemetrexed can help patients with small cell lung cancer live l...
Eligibility Criteria
Inclusion
- Diagnosis of small cell lung cancer
- One prior treatment with chemotherapy or immunotherapy with greater than 3 weeks since the prior treatment
- At least 18 years of age
- Estimated life expectancy of at least 12 weeks
- Ambulatory and capable of self-care(eg, up and about greater than 50% of waking hours)
Exclusion
- Have received treatment within the last 30 days with a drug that has not received FDA approval for any indication
- Less than 2 weeks from radiation therapy
- Other serious illness that would compromise the safety of the patient
- Most second primary malignancies treated less than 5 years previously
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00191750
Start Date
July 1 2004
End Date
September 1 2006
Last Update
January 26 2007
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Aurora, Colorado, United States
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Chapel Hill, North Carolina, United States
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Dallas, Texas, United States